<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00199823</url>
  </required_header>
  <id_info>
    <org_study_id>S-03115</org_study_id>
    <nct_id>NCT00199823</nct_id>
  </id_info>
  <brief_title>Autologous Stem Cell Transplantation in Acute Myocardial Infarction</brief_title>
  <official_title>Autologous Stem Cell Transplantation in Acute Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Oslo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ullevaal University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oslo University Hospital</source>
  <brief_summary>
    <textblock>
      Objectives

      Intracoronary transplantation of different cell populations have been used in acute
      myocardial infarction (AMI) with promising results. The primary objective of the ASTAMI study
      is to test whether intracoronary transplantation of autologous mononuclear bone marrow cells
      (mBMC) improve left ventricular ejection fraction (LVEF) after anterior wall AMI.

      Design

      The ASTAMI study is a randomized, controlled, prospective study. One hundred patients with
      acute anterior wall ST-elevation myocardial infarction (STEMI) treated with acute PCI are
      randomized in a 1:1 way to either intracoronary transplantation of autologous mBMC 5-8 days
      after PCI or to control. Left ventricular function, exercise capacity, biochemical status,
      functional class, quality of life and complications are validated at baseline and during a
      12-month follow up.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2003</start_date>
  <completion_date>May 2006</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single</masking>
  </study_design_info>
  <primary_outcome>
    <measure>whether intracoronary mBMC transplantation improve LVEF after AMI assessed by ECG-gated SPECT.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To test whether mBMC treatment improve exercise capacity assessed by bicycle ergometry</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To test whether mBMC treatment improve quality of life assessed by the SF 36 formula</measure>
  </secondary_outcome>
  <enrollment>100</enrollment>
  <condition>Acute Anterior Wall Myocardial Infarction</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Intracoronary aotologous stem cell transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  age 40-75 years

          -  anterior wall AMI with 120-720 minutes from onset of symptoms to PCI

          -  ST elevation on ECG according to WHO criteria

          -  angiographically significant stenosis on LAD proximal to the second diagonal branch

          -  successful PCI with stenting of culprit lesion

          -  hypokinetic, akinetic or dyskinetic segments assessed by echocardiography in a
             standard 16 segment model and

          -  CK-MB above 3 times upper reference value.

        Exclusion criteria:

          -  previous MI with established significant Q-waves on ECG

          -  cardiogenic shock

          -  permanent pacemaker or other contraindication to MRI

          -  stroke with significant sequela

          -  short life expectancy due to extra cardiac reason

          -  uncontrolled endocrinological disturbance

          -  HIV and/or HBV/HCV positive serology

          -  mental disorder or other condition which interferes with patient possibility to comply
             with the protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ketil Lunde, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oslo University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rikshospitalet-Radiumhospitalet HF</name>
      <address>
        <city>Oslo</city>
        <zip>0027</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <results_reference>
    <citation>Lunde K, Solheim S, Aakhus S, Arnesen H, Abdelnoor M, Egeland T, Endresen K, Ilebekk A, Mangschau A, Fjeld JG, Smith HJ, Taraldsrud E, Grøgaard HK, Bjørnerheim R, Brekke M, Müller C, Hopp E, Ragnarsson A, Brinchmann JE, Forfang K. Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. N Engl J Med. 2006 Sep 21;355(12):1199-209.</citation>
    <PMID>16990383</PMID>
  </results_reference>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 19, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>July 3, 2011</last_update_submitted>
  <last_update_submitted_qc>July 3, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 6, 2011</last_update_posted>
  <keyword>Myocardial infarction</keyword>
  <keyword>bone marrow cells</keyword>
  <keyword>cell transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Anterior Wall Myocardial Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

